Bivalirudin Abciximab

Patients with diabetes remain an important subgroup given the evidence supporting reduced revascularization and mortality associated with abciximab in these patients undergoing PCI (38). Compared with a strategy of heparin and GP llb/llla inhibition, diabetic patients treated with bivalirudin experienced a numerically lower but nonsignificant late mortality at 12 months (2,3% vs, 3,9%, P = NS), No differences were observed with short-term bleeding and ischemic outcomes. 

Clinically important, potentially hazardous interactions with abciximab, aspirin, bivalirudin, dipyridamole, piperacillin, salicylates... 

Low-dose aspirin did not alter the pharmacokinetics or pharmacodynamic effects of ai atroban. Neither abciximab nor eptifibatide appeared to alter ai atroban pharmacokinetics. There is no pharmacodynamic interaction between bivalirudin and aspirin, ticlopidine, ciopidogrei, abciximab, eptifibatide or tirofiban. Nevertheless, the manufacturers warn of the increased bleeding risks if argatroban, bivalirudin or lepirudin are used with antiplatelet drugs or thrombolytics. 

I. Antiplatelet drugs. The UK manufacturer says that no pharmacodynamic interactions were detected when bivalirudin was used with platelet inhibitors, including aspirin, ticlopidine, ciopidogrei, abciximab, eptifibati-... 

---